4th Quarter - Amendment

ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP

Firm
Client
Income
—
Expenses
$510,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
4th Quarter - Report Jan 21, 2012 $520,000 Replaced
4th Quarter - Amendment (this page) Feb 20, 2012 $510,000 Yes

What was lobbied

8 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Issues related to US position on intellectual property protections offered by US in international trade treaty

LobbyistCovered position, as disclosed
RICHARD BUCKLEY —
BRADLEY ALLEN ROSSIN —

Contacted: SENATE; Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Issues related to reform of tax code and possible timing of any such reform bill (no bill number yet)

LobbyistCovered position, as disclosed
RICHARD BUCKLEY —
DANNY LY —

Contacted: HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); SENATE

Copyright/Patent/Trademark CPT

HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics S. 27 (Preserve Access to Affordable Generics Act) - Legislative proposals surrounding patent reform and intellectual property issues, including patent settlements Issues related to US position on intellectual property protections offered by US in international trade treaty

Contacted: Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2182 (112th), S. 27 (112th)

Health Issues HCR

HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections

Contacted: HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); SENATE; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 1483 (112th), H.R. 3590 (112th), H.R. 2245 (112th), H.R. 2182 (112th), H.R. 3026 (112th), H.R. 2674 (112th), H.R. 1254 (112th), H.R. 3206 (112th)

Medicare/Medicaid MMM

HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 3342, S 1356 - issues related to utilization of generic drugs in Medicaid program

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 2190 (112th), H.R. 3590 (112th), H.R. 3342 (112th), S. 1206 (112th)

Consumer Issues/Safety/Products CSP

HR 1483, S.1584, S. Amdt. 769 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections S 1946 (Foreign Manufacturers Legal Accountability Act) - issues related to registration of foreign manufacturers

LobbyistCovered position, as disclosed
CHRISTINE BLOOMQUIST —
RICHARD BUCKLEY —
THERESA JOLIVETTE —
ANDREW KAPLAN —
DANNY LY —
BRADLEY ALLEN ROSSIN —
BELA SASTRY —
HEATHER STRAWN —

Contacted: SENATE; Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 1483 (112th), S. 296 (112th), S. 1584 (112th), H.R. 3026 (112th), H.R. 2245 (112th)

Labor Issues/Antitrust/Workplace LBR

Discussions regarding possible clarifications to labor rules, including wage and hour issues

LobbyistCovered position, as disclosed
RICHARD BUCKLEY —
KIRSTEN POWELL —

Contacted: Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE

Pharmacy PHA

FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) (no bill number yet)

LobbyistCovered position, as disclosed
RICHARD BUCKLEY —
ANDREW KAPLAN —
DANNY LY —
KIRSTEN POWELL —
BRADLEY ALLEN ROSSIN —
HEATHER STRAWN —

Contacted: Centers For Medicare and Medicaid Services (CMS); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.